The Redsense technology is becoming available to more patients in the US, as several leading dialysis providers have decided to incorporate the device in their clinical practice.

The Redsense device is now introduced at the facilities of the Rogosin Institute, long recognized as one of the premier centers in the US for kidney disease diagnosis and management. The institute, which ranks among the top 10 dialysis providers in the US, operates nine dialysis centers in the NYC area with about 1,500 patients on hemodialysis. In addition to this, 10 patients undergoing treatment at the Dialysis Center of Lincoln, Inc. have also begun to use the Redsense device. DCL Inc. operates several centers in the Omaha, Nebraska area.

“The decision by these providers to adopt Redsense’s technology primarily benefits patient security, as the device adds another layer of security to hemodialysis. For us as a company, it further strengthens our goal to establish the Redsense alarm system as a standard protection measure agains venous needle dislodgement,” says Patrik Byhmer, CEO of Redsense Medical AB.

For more information, please contact:

Patrik Byhmer, CEO Redsense Medical AB (publ)

Phone: +46 35 10 60 30

info@redsensemedical.com  

www.redsensemedical.com

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System,an innovationused for monitoring and alarm in the case of blood leakage in connection with a hemodialysistreatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous NeedleDislodgement and catheter leakage tominimizeblood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company"s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.